| Q4 2021 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | (EXPECTED)2022-02-28 | ||||||
| REV | |||||||
| Q3 2021 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | -0.180 | -0.190 | -0.0100 | ||||
| REV | 80.110M | 79.545M | -565.000K |
| Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
|---|
You can purchase shares of Amicus Therapeutics (NASDAQ: FOLD) through any online brokerage.
Other companies in Amicus Therapeutics’s space includes: Twist Bioscience (NASDAQ:TWST), Zentalis Pharmaceuticals (NASDAQ:ZNTL), Karuna Therapeutics (NASDAQ:KRTX), Sage Therapeutics (NASDAQ:SAGE) and Cerevel Therapeutics Hldg (NASDAQ:CERE).
The latest price target for Amicus Therapeutics (NASDAQ: FOLD) was reported by SVB Leerink on January 14, 2022. The analyst firm set a price target for 16.00 expecting FOLD to rise to within 12 months (a possible 75.25% upside). 13 analyst firms have reported ratings in the last year.
The stock price for Amicus Therapeutics (NASDAQ: FOLD) is $9.13 last updated Fri Jan 28 2022 21:00:02 GMT+0000 (Coordinated Universal Time).
There are no upcoming dividends for Amicus Therapeutics.
Amicus Therapeutics’s $Q4 earnings are confirmed for after-market on February 28, 2022.
There is no upcoming split for Amicus Therapeutics.
Amicus Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.